Market reaction and trial launch
Shares of Ideaya Biosciences Inc (NASDAQ:IDYA) rose 4.9% on Monday following the company's announcement that it has started a phase 1 clinical trial evaluating a combination of IDE892 and IDE397 in MTAP-deleted solid tumors. The company said it has enrolled the first patient in the combination study, according to a statement released on Monday.
Scope and patient population
The combination study will focus on patients with non-small cell lung cancer and pancreatic cancer who harbor MTAP deletions. Ideaya described the trial as a phase 1 evaluation of IDE892, an MTA-cooperative inhibitor of PRMT5, in combination with IDE397, an inhibitor of MAT2A.
Preclinical rationale
In its statement, Ideaya said that preclinical experiments using the dual inhibition approach - combining IDE892 and IDE397 - produced anti-tumor activity in MTAP-deleted tumor models. The company reported that these studies included complete and durable responses at doses lower than those required for single-agent activity.
Development status of IDE892
Separately, Ideaya said IDE892 monotherapy is undergoing a phase 1 escalation in which multiple dose cohorts have been cleared and the maximum tolerated dose has not yet been reached. The company expects to begin a monotherapy expansion in the third quarter of 2026.
Prevalence and unmet need
Ideaya provided prevalence estimates for MTAP deletion, stating it is found in up to 40% of pancreatic cancers and approximately 15% of non-small cell lung cancers. The company noted there are currently no approved therapies specifically for MTAP-deleted cancers.
Collaborations and additional programs
The company also announced a clinical collaboration with Roche to test IDE892 alongside RG6505, Roche's phase 1 pan-RAS inhibitor, in MTAP-deleted pancreatic ductal adenocarcinoma. This study is intended to address tumors with co-alterations in MTAP and KRAS. In addition, Ideaya is advancing a third proprietary program targeting CDKN2A in MTAP-deleted solid tumors; that program is undergoing preclinical toxicology studies to support an investigational new drug application in the first half of 2027.
Context for investors and sectors affected
The developments touch the biotechnology and pharmaceutical sectors, and may be of interest to oncology-focused investors and market participants watching clinical progress in targeted cancer therapies. The initiation of a combination phase 1 trial, the enrollment of the first patient, and the outlined timelines for monotherapy expansion and a potential IND all represent milestones for the company program portfolio.
Note: This article reports company statements and program timelines as provided by Ideaya.